美国Roche 454 Life Sciences  www.454.com    www.roche-diagnostics.cn  www.roche.com
2007年 罗氏诊断（Roche Diagnostics）与CuraGen公司已签订协议，以1.55亿美元的现金和股票收购454 Life Sciences。
454生命科学是罗氏应用科学旗下卓越的中心之一，开发并商业化了创新的454测序系统，用于超高通量的DNA测序。具体的应用包括基因组的从头测序和重测序、宏基因组学、RNA分析和DNA目标区域的定向测序。454测序系统的特点是样品制备简单且无偏向性，读长超长且准确度高。454测序系统的技术已经催生了各个研究领域的几百 项经同行评议的研究文章，例如癌症和传染病研究、药物筛选、海洋生物学、人类学、古生物学等各方面研究。如需更多信息，请访问http://www.454.com。预查询该技术信息，请访问www.roche-applied-science.com/sis/sequencing 。

关于罗氏
总部设在瑞士巴塞尔的罗氏，是一个世界领先的、注重科研的医药和诊断产品开发集团。作为世界上最大的生物技术公司，该集团为疾病的早期发现、预防、诊断和治疗提供了创新的产品和服务，在改善人类健康和生活质量的各个方面都做出了大量 贡献。罗氏公司是体外诊断的世界领先公司，是治疗癌症和器官移植所需药物的领先 供应者，也是病毒学的市场领导者，并活跃在其他主要的治疗领域，如自身免疫性疾病，炎症，代谢及中枢神经系统。2007年该集团药品部的销售总额为368亿瑞士法郎，诊断部的销售额为93亿瑞士法郎。罗氏公司与众多的合作伙伴签订了研发协议并结成战略联盟，包括在美国基因技术公司（Genentech, Inc.）和日本中外制药株式会社 （Chugai Pharmaceutical Co., Ltd.）拥有多数股权，2007年研发投资达80亿瑞士法郎。罗氏集团的全球员工总数约8万。如需了解更详细的信息，请访问www.roche.com 。

 
454 Life Sciences, a center of excellence of Roche Applied Science, develops and commercializes the innovative Genome Sequencer? system for ultra-high-throughput DNA sequencing. Specific applications include de novo sequencing and re-sequencing of genomes, metagenomics, RNA analysis, and targeted sequencing of DNA regions of interest. The hallmarks of 454 Sequencing? are its simple, unbiased sample preparation and long, highly accurate sequence reads, including paired reads. 454's current system, the Genome Sequencer FLX with GS FLX Titanium series reagents generates 400 million high quality bases per 10 hour instrument run. 454 Sequencing technology has enabled hundreds of peer-reviewed studies in diverse research fields such as cancer and infectious disease research, drug discovery, marine biology, anthropology, paleontology and many more.

About Roche and the Roche Diagnostics Division
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

Timeline
June 2000 454 Life Sciences is founded
October 2005 Release of the Genome Sequencer 20, the first next-generation sequencing system on the market
October 2005 Collaboration agreement signed with Roche Diagnostics
December 2005 454 Life Sciences Awarded the Wall Street Journal's Gold Medal for Innovation
November 2006 454 Life Sciences, in collaboration with Svante Paabo, describes in Nature the first million base pairs of the Neanderthal genome and initiates the Neanderthal Genome Project.
January 2007 Release of the Genome Sequencer FLX System
March 2007 Roche Diagnostics completes integration with 454 Life Sciences
May 2007 Complete sequence of Jim Watson published in Nature. First genome to be sequenced for less than $1 million.
November 2007 Announcement of the 100th peer-reviewed publication enabled by 454 Sequencing
June 2008 454 Joins the 1000 Genome Project, an international effort to build the most detailed map to date of human genetic variation as a tool for medical research
September 2008 Announcement of the 250th peer-reviewed publication enabled by 454 Sequencing
October 2008 Release of Genome Sequencer FLX Titanium Series reagents, featuring 1 million reads at 400 base pairs in length